# Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

> **NCT03036839** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 95 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT03036839
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-27
- **Primary completion:** 2018-11-22
- **Final completion:** 2019-02-14
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03036839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03036839, "Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03036839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*